Physician profile
Patrick Curran
NPI 1023689510
$1,335.09
in general payments reported to CMS, 2019-2025
10 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.40 · 2022: $557 · 2023: $199 · 2024: $408 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.83 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $251.99 | 2024-2025 | Rybrevant, Carvykti |
| Eisai INC. | $215.08 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $149.46 | 2024 | Provenge |
| Exelixis INC. | $146.69 | 2021-2022 | |
| Astellas Pharma US INC | $142.87 | 2022-2025 | Xtandi |
| Merck Sharp & Dohme LLC | $133.12 | 2024 | Welireg |
| Astrazeneca Pharmaceuticals Lp | $99.95 | 2023 | Lynparza |
| Genzyme Corporation | $99.36 | 2022 | |
| Sanofi-Aventis U.S. LLC | $84.99 | 2022 | |
| Janssen Scientific Affairs, LLC | $11.58 | 2025 | Erleada |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Curran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.